💡 在您使用本产品前请认真阅读说明书,这对您顺利完成实验很有帮助。
|
🏷️ 产品编码
RB9T37015192
|
🧬 中文名称
抗人Osteoactivin/GPNMB参考抗体
|
|
📝 英文名称
Anti-Human Osteoactivin/GPNMB Reference Antibody
| |
|
📦 形态
Liquid
|
🧪 纯度
>95% purity as determined by SDS-PAGE.
|
|
🔹 内毒素水平
Please contact the lab for this information.
| |
|
🔬 应用
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
| |
|
🧫 表达系统
Mammalian Cells
|
🔢 登录号
Q14956
|
|
🔹 宿主种属
Human
|
🔹 克隆性
Monoclonal
|
|
🔹 抗体亚型
IgG2-kappa
|
🔹 纯化方式
Protein A/G purified from cell culture supernatant.
|
|
🔹 浓度
1mg/ml
|
🔹 种属反应性
Human
|
|
🔹 靶标
NMB, Hematopoietic growth factor inducible neurokinin-1 type, HGFIN, GPNMB, Transmembrane glycoprotein NMB
|
🔹 背景信息
Glembatumumab (CR011) is a fully human IgG2 monoclonal antibody (mAb) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB, or osteoactivin). It was designed to linke to monomethyl auristatin E (MMAE) via a valine-citrulline enzyme-cleavable linker to act as an antibody-drug conjugate (ADC) termed glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) for the treatment of advanced, refractory, or resistant GPNMB-expressing breast cancer. It was originally developed through a partnership between CuraGen and Amgen, using Xenomouse technology licensed from Abgenix and ADC technology licensed from Seattle Genetics. Glembatumumab vedotin was in development through April 2018 by Celldex Therapeutics, who acquired CuraGen in 2009. Development of the ADC was discontinued in April 2018 after missing the primary endpoint of its study and failed to help women with tough-to-treat metastatic triple-negative breast cancers (TNBC) stay both alive and progression-free for longer than Roche Holding AG’s Xeloda (capecitabine).
|
|
🏷️ 别名
CDX-011(DOX), CR011, glembatumumabvedotin(ADC), 1020264-78-1
| |
🧴 储存缓冲液
0.01M PBS, pH 7.4.
❄️ 稳定性和储存
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
⚠️ For research use only. Not suitable for clinical or therapeutic use.